to maximize odds of success in phase 3, the common practice has always been to design it to be as much as possible like the signal finding phase 2 trial. what they did in sumit boggles the mind that they would design a phase 3 trial based on pre-clinical data. too often do pre-clinical results not translate to clinical trials. it's hard to believe selumetinib does not work as determined by sumit when we've already seem strong single agent activity. who knows, maybe they cooked the data in the phase 2 trial
there was no clinical data to support running SUMIT with a combo of dacarbazine and selumetinib. the phase 2 trail that justified SUMIT used selumetinib as a single agent vs temozolomide and showed a 54% reduction in pfs. So, with these strong result, why didn't they run a similar phase 3. does anyone have any idea what the hell they were thinking?
the only chump i see is you seman... who stated that exel will be TRADE under a dollar b/f the end of 2014... how did that prediction work out for you genius? honesty and integrity are definitely traits you do not have or else you wouldn't be here at this board spewing your nonsense after betting that you would never post here again if the price does not drop under 1 as you predicted. who's the chump now?